We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

153 hedge funds and large institutions have $396M invested in Sciclone Pharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 49 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

544% more call options, than puts

Call options by funds: $290K | Put options by funds: $45K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 49

1% more funds holding

Funds holding: 151153 (+2)

0% less capital invested

Capital invested by funds: $396M → $396M (-$505K)

Holders
153
Holders Change
+2
Holders Change %
+1.32%
% of All Funds
3.83%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
29
Increased
55
Reduced
49
Closed
23
Calls
$290K
Puts
$45K
Net Calls
+$245K
Net Calls Change
+$171K
Name Holding Trade Value Shares
Change
Change in
Stake
VOYA Investment Management
101
VOYA Investment Management
Georgia
$266K
Capstone Investment Advisors
102
Capstone Investment Advisors
New York
$222K +$206K +20,640 New
LSERS
103
Louisiana State Employees Retirement System
Louisiana
$221K -$16K -1,600 -7%
AG
104
Algert Global
California
$219K +$60.5K +6,054 +42%
Public Employees Retirement Association of Colorado
105
Public Employees Retirement Association of Colorado
Colorado
$209K
VKH
106
Virtu KCG Holdings
New York
$208K +$192K +19,229 New
Balyasny Asset Management
107
Balyasny Asset Management
Illinois
$202K +$26.3K +2,630 +16%
CSS
108
Cubist Systematic Strategies
Connecticut
$201K -$87K -8,702 -32%
TRSOTSOK
109
Teachers Retirement System of the State of Kentucky
Kentucky
$192K
B
110
Barings
North Carolina
$191K
JMPWA
111
JP Morgan Private Wealth Advisors
California
$188K +$174K +17,443 New
SG Americas Securities
112
SG Americas Securities
New York
$188K +$174K +17,449 New
Los Angeles Capital Management
113
Los Angeles Capital Management
California
$164K
AIM
114
Acrospire Investment Management
Illinois
$147K +$8.48K +848 +7%
AIM
115
Alambic Investment Management
California
$140K +$130K +13,000 New
Macquarie Group
116
Macquarie Group
Australia
$138K -$68K -6,800 -35%
AG
117
Aperio Group
California
$132K -$10.1K -1,007 -8%
MERSOM
118
Municipal Employees' Retirement System of Michigan
Michigan
$123K -$358K -35,830 -76%
UBS AM
119
UBS AM
Illinois
$122K -$228K -22,800 -67%
MSA
120
Mason Street Advisors
Wisconsin
$120K +$8.75K +875 +9%
O
121
OppenheimerFunds
New York
$111K +$102K +10,244 New
DTL
122
Dynamic Technology Lab
Singapore
$109K -$179K -17,878 -64%
NA
123
NewEdge Advisors
Louisiana
$103K
BNP Paribas Financial Markets
124
BNP Paribas Financial Markets
France
$99K +$21.4K +2,144 +31%
PCM
125
Prelude Capital Management
New York
$77K -$128K -12,755 -64%

SCLN Hedge Fund Activity: Q4 2016 in Review

153 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2016, worth a combined $396M — down 0.13% from $396M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new SCLN positions and 23 closed out — a net gain of 6 holders — while 55 added to existing stakes and 49 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $12.5M. The largest seller was Numeric Investors, cutting an estimated $16.2M.

  • 153 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2016, up from 151 in Q3 2016.
  • Funds reported $396M of Sciclone Pharmaceuticals Inc stock for Q4 2016, down 0.13% quarter-over-quarter.
  • 29 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2016 and 23 closed out, a net change of +6 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q4 2016 was Stonepine Capital Management, an estimated $12.5M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2016 was Numeric Investors, an estimated $16.2M sold.

Based on aggregated 13F filings for Q4 2016.